UY28671A1 - Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2 - Google Patents

Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2

Info

Publication number
UY28671A1
UY28671A1 UY28671A UY28671A UY28671A1 UY 28671 A1 UY28671 A1 UY 28671A1 UY 28671 A UY28671 A UY 28671A UY 28671 A UY28671 A UY 28671A UY 28671 A1 UY28671 A1 UY 28671A1
Authority
UY
Uruguay
Prior art keywords
diaminas
pirimidina
pirido
pde
inhibitors
Prior art date
Application number
UY28671A
Other languages
English (en)
Inventor
Andrew Ian Morrell
Thomas Arthur Beyer
Robert James Chambers
Kelvin Lam
Mei Li
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY28671A1 publication Critical patent/UY28671A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La invención proporciona compuestos de fórmula (I) los profármacos de los mismos, y las sales de los compuestos o profármacos farmacéuticamente aceptables, en la que n, X, e Y son como se ha definido en esta memoria descriptiva; las composiciones farmacéuticas de los mismos; las combinaciones de los mismos; y los usos de lso mismos.
UY28671A 2003-12-16 2004-12-15 Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2 UY28671A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52999403P 2003-12-16 2003-12-16

Publications (1)

Publication Number Publication Date
UY28671A1 true UY28671A1 (es) 2005-07-29

Family

ID=34710150

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28671A UY28671A1 (es) 2003-12-16 2004-12-15 Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2

Country Status (39)

Country Link
US (1) US20070135457A1 (es)
EP (1) EP1697356B1 (es)
JP (1) JP4073944B2 (es)
KR (1) KR100816179B1 (es)
CN (1) CN100439366C (es)
AP (1) AP2006003632A0 (es)
AR (1) AR046766A1 (es)
AT (1) ATE387446T1 (es)
AU (1) AU2004303609A1 (es)
BR (1) BRPI0417663A (es)
CA (1) CA2549510A1 (es)
CL (1) CL2008001920A1 (es)
DE (1) DE602004012154T2 (es)
DK (1) DK1697356T3 (es)
EA (1) EA010424B1 (es)
EC (1) ECSP066643A (es)
ES (1) ES2299888T3 (es)
GE (1) GEP20094720B (es)
GT (1) GT200400268A (es)
HN (1) HN2004000538A (es)
HR (1) HRP20080142T3 (es)
IL (1) IL175813A0 (es)
IS (1) IS8474A (es)
MA (1) MA28270A1 (es)
MX (1) MXPA06006777A (es)
NL (1) NL1027787C2 (es)
NO (1) NO20063231L (es)
PE (1) PE20050681A1 (es)
PL (1) PL1697356T3 (es)
PT (1) PT1697356E (es)
RS (1) RS50575B (es)
SI (1) SI1697356T1 (es)
SV (1) SV2005001979A (es)
TN (1) TNSN06186A1 (es)
TW (1) TWI291961B (es)
UA (1) UA83091C2 (es)
UY (1) UY28671A1 (es)
WO (1) WO2005061497A1 (es)
ZA (1) ZA200604970B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2562428T3 (es) * 2005-12-15 2016-03-04 Rigel Pharmaceuticals, Inc. Inhibidores de cinasa y sus usos
KR20090098783A (ko) * 2006-09-21 2009-09-17 토시키 오구로 경조직 재생 촉진제
WO2009116577A1 (ja) * 2008-03-18 2009-09-24 日産化学工業株式会社 １－（置換フェニル）－１－置換シリルエーテル、アルコールまたはケトンの製造方法および中間体
EP2355657A4 (en) * 2008-10-31 2012-05-09 Corridor Pharmaceuticals Inc Compositions and methods for treating endothelial dysfunction
EP2456440B1 (en) 2009-07-22 2015-08-19 Merck Sharp & Dohme Corp. Quinolinone pde2 inhibitors
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
EP2699577A1 (en) 2011-04-20 2014-02-26 Glaxo Group Limited Tetrahydropyrazolo [1,5 -a]pyrimidine as anti -tuberculosis compounds
PE20142258A1 (es) 2012-04-25 2015-01-15 Takeda Pharmaceutical Compuesto heterociclico nitrogenado
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014142255A1 (ja) 2013-03-14 2014-09-18 武田薬品工業株式会社 複素環化合物
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
EP3018126A4 (en) 2013-07-03 2016-12-07 Takeda Pharmaceuticals Co HETEROCYCLIC COMPOUND
JPWO2015012328A1 (ja) * 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
US9815796B2 (en) 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
WO2015106032A1 (en) 2014-01-08 2015-07-16 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
RU2712165C2 (ru) * 2014-08-01 2020-01-24 Фирмениш Са Твердая дисперсия амидных пищевых ароматизаторов
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
KR102557603B1 (ko) 2014-12-06 2023-07-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
EP3285581B1 (en) 2015-03-26 2021-08-11 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
US10195201B2 (en) 2015-05-05 2019-02-05 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
AU2018371216A1 (en) 2017-11-23 2020-06-04 Oslo University Hospital Hf Treatment of tachycardia
CN109758458B (zh) * 2019-03-05 2021-02-23 中国人民解放军陆军军医大学第二附属医院 抑制Crif1与PKA相互作用的化合物的应用
US11648254B2 (en) 2021-03-02 2023-05-16 Kumquat Biosciences Inc. Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling
US11912708B2 (en) 2022-04-20 2024-02-27 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2749344A (en) * 1953-01-02 1956-06-05 Burroughs Wellcome Co Pyrimidine compounds
US2926166A (en) * 1954-01-04 1960-02-23 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
US3021332A (en) * 1954-01-04 1962-02-13 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
US2924599A (en) * 1956-07-16 1960-02-09 Anchor Chemical Company Ltd Derivatives of 1:3:5-triazanaphthalene
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
US3288792A (en) * 1962-07-05 1966-11-29 Burroughs Wellcome Co Method of preparing 2, 4-diamino-6-alkylpyrido (2, 3-d) pyrimidines
DE3422824A1 (de) * 1984-06-20 1986-01-02 Celamerck Gmbh & Co Kg, 6507 Ingelheim Neue herbizid wirksame sulfonylharnstoffe
US6194166B1 (en) * 1993-05-24 2001-02-27 Takara Shuzo Co., Ltd. Gene regulating aureobasidin sensitivity
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US6262059B1 (en) * 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4

Also Published As

Publication number Publication date
JP2007513996A (ja) 2007-05-31
ES2299888T3 (es) 2008-06-01
BRPI0417663A (pt) 2007-04-03
HRP20080142T3 (en) 2008-06-30
AU2004303609A1 (en) 2005-07-07
AP2006003632A0 (en) 2006-06-30
IL175813A0 (en) 2006-10-05
SI1697356T1 (sl) 2008-06-30
HN2004000538A (es) 2008-02-21
GT200400268A (es) 2005-09-20
CA2549510A1 (en) 2005-07-07
KR20060105776A (ko) 2006-10-11
DE602004012154T2 (de) 2009-03-12
ATE387446T1 (de) 2008-03-15
EA010424B1 (ru) 2008-08-29
TNSN06186A1 (fr) 2007-11-15
SV2005001979A (es) 2005-12-13
AR046766A1 (es) 2005-12-21
KR100816179B1 (ko) 2008-03-28
CN1894245A (zh) 2007-01-10
DK1697356T3 (da) 2009-01-12
EP1697356A1 (en) 2006-09-06
PT1697356E (pt) 2008-05-05
RS50575B (sr) 2010-05-07
TW200522952A (en) 2005-07-16
MA28270A1 (fr) 2006-11-01
JP4073944B2 (ja) 2008-04-09
PL1697356T3 (pl) 2008-07-31
MXPA06006777A (es) 2006-08-23
NO20063231L (no) 2006-07-11
ECSP066643A (es) 2006-10-25
CN100439366C (zh) 2008-12-03
ZA200604970B (en) 2007-11-28
NL1027787A1 (nl) 2005-06-21
GEP20094720B (en) 2009-06-25
TWI291961B (en) 2008-01-01
US20070135457A1 (en) 2007-06-14
WO2005061497A1 (en) 2005-07-07
IS8474A (is) 2006-05-18
NL1027787C2 (nl) 2006-03-09
UA83091C2 (en) 2008-06-10
PE20050681A1 (es) 2005-10-04
EA200600973A1 (ru) 2006-10-27
CL2008001920A1 (es) 2008-10-17
DE602004012154D1 (de) 2008-04-10
EP1697356B1 (en) 2008-02-27

Similar Documents

Publication Publication Date Title
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
CR7069A (es) Derivados de pirazol para el tratamiento de vih
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
UY27350A1 (es) Azaindoles
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY31471A1 (es) Derivados bis-(sulfonilamino) en terapia 066
DOP2006000193A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
GT200500375A (es) Derivados de piperidina y su uso como agentes antiinflamatorios
CR9834A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
UY30327A1 (es) Nuevos compuestos ii
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
CR9954A (es) Derivados de pirazina
UY30460A1 (es) Compuestos terapéuticos
UY31546A1 (es) Derivados bis-(sulfonilamino) en terapia 205
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
PA8667201A1 (es) Nuevos compuestos farmaceuticos
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY31457A1 (es) Derivados acidos de cicloalquilamino
DOP2002000422A (es) Agentes antibacterianos.
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150605